- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02247440
HCV-HIV Co-infected Patient Cohort in Thailand
Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand
This is a study of HCV treatment using the standard regimen of pegylated-interferon plus ribavirin in HIV co-infected patients participating in the PHPT cohort study. The treatment will be implemented in conjunction with gastro-enterologists/hepatologists by internists responsible for the participant's HIV treatment.
Chronic hepatitis C virus (HCV) infection is responsible for several severe and life threatening complications, which are worsened by HIV co-infection. HIV-HCV co-infected patients are at a higher risk of death compared to HIV mono-infected individuals, even if HIV replication is suppressed on antiretroviral treatment.
The goal of HCV antiviral treatment is to cure HCV infection. Curing HCV infection allows fibrosis regression, improved clinical outcomes. In addition, individuals who have been cured are no longer contagious to other individuals, therefore widespread access to HCV treatment may contribute to the control of the HCV epidemic.
A combination of injectable pegylated-interferon with oral ribavirin is currently the recommended regimen for the treatment of hepatitis C in the setting of HIV co-infection. They are administered for 24 weeks in HCV mono-infected patients but need to be administered for one year in HIV-HCV co-infected patients. Newer drugs, such as the first generation HCV protease inhibitors (boceprevir, telaprevir), administered concomitantly, are used in patients who have not been cured using peg-interferon + ribavirin, and may allow for shorter treatment.
PRIMARY OBJECTIVE
1. To determine the percentage of patients according to genotypes with sustained virological response 6 months after treatment discontinuation (SVR).
HCV TREATMENT
- Peg-interferon alpha 2-b (a subcutaneous injection of 1.5 micrograms/kg once a week)
- Ribavirin dosing according to HCV genotype and body weight; dose adjustment in case of anemia.
A total of 60 patients could be enrolled in the study: 15 HCV-HIV co-infected patients in a first part (starting in August 2014) and 45 patients in a second part, depending on funding.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Population Screening: HIV infected patients with a positive anti-HCV test will be approached for screening if they are at least 18 years old, participate in the PHPT cohort study, have evidence of control of HIV replication and have a CD4 cell count ≥200 cells/mm3 if currently receiving antiretroviral HIV treatment (on the same anti-HIV regimen for at least 12 weeks); or HIV RNA load ≤5000 copies/ml CD4 cells ≥500 cells/mm3if not receiving antiretroviral treatment.
Inclusion Criteria
- Evidence of chronic HCV infection for at least 6 months before study entry (at least one detectable HCV viral load, i.e. ≥17 IU/mL, with an antibody test positive at least 6 months before the HCV RNA load result)
- Fibrosis Stage F2-3-4 determined by transient elastography (Fibroscan or other similar equipment). During the first part of the study, priority will be given to patients with Fibrosis Stage F2-3.
- Negative pregnancy test (on the day of inclusion). Main exclusion criteria
- Anemia and thrombocytopenia
- Severe liver damage, advanced stage cirrhosis or cancer
- Uncontrolled diabetes, Uncontrolled thyroid dysfunction
- Retinopathy
- Creatinine clearance <50 mL/min (Cockcroft)
- Disease associated with the immune system
- Significant heart problems
- Severe neuropsychiatric conditions
- Contra-indication to study treatment (including pregnancy or lack of effective contraception in the participant or female partner)
- Other exclusion criteria related to the use of ribavirin and peg-interferon
- Any conditions that, in the investigator's judgment, may compromise the follow up.
Follow up After HCV treatment initiation, patients will be monitored for safety and antiviral efficacy at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 weeks (end of treatment) and 6 months after treatment discontinuation.
Treatment will be discontinued earlier in patients who do not achieve early viral response, i.e. a decrease of at least 2 log10 HCV RNA IU/mL after the first 12 weeks of HCV therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Chiang Mai, Thailand, 50180
- Nakornping Hospital
-
Chiang Rai, Thailand, 57000
- Chiangrai Prachanukroh Hospital
-
Chon Buri, Thailand, 20000
- Chonburi Hospital
-
Samut Sakhon, Thailand, 74000
- Samutsakhon Hospital
-
-
Chiang Mai
-
San Pa Tong, Chiang Mai, Thailand, 50120
- Sanpatong Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of chronic HCV infection for at least 6 months before study entry (at least one detectable HCV viral load, i.e. ≥17 IU/mL, with an antibody test positive at least 6 months before the HCV RNA load result)
- Fibrosis Stage F2-3-4 determined by transient elastography (Fibroscan or other similar equipment). During the first part of the study, priority will be given to patients with Fibrosis Stage F2-3.
- Negative pregnancy test (on the day of inclusion).
Exclusion Criteria:
- Anemia and thrombocytopenia
- Severe liver damage, advanced stage cirrhosis or cancer
- Uncontrolled diabetes, Uncontrolled thyroid dysfunction
- Retinopathy
- Creatinine clearance <50 mL/min (Cockcroft)
- Disease associated with the immune system
- Significant heart problems
- Severe neuropsychiatric conditions Contra-indication to study treatment (including pregnancy or lack of effective contraception in the participant or female partner)
- Other exclusion criteria related to the use of ribavirin and peg-interferon
- Any conditions that, in the investigator's judgment, may compromise the follow up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PegINF-ribavirin
Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week Ribavirin initial dosing in the morning and in the evening:
Duration: 48 weeks |
Peg-interferon + ribavirin under HIV physician supervision
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation
Time Frame: 6 months after end of treatment, i.e. 1.5 years after treatment initiation
|
Number of Participants with Sustained Virological Response 6 Months After Treatment Discontinuation,
|
6 months after end of treatment, i.e. 1.5 years after treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With at Least a Serious Adverse Events Associated With Study Treatment (Peg-interferon and Ribavirin)
Time Frame: From initiation of treatment to 6 months after treatment discontinuation
|
Number of participants with at least a serious adverse events associated with study treatment (peg-interferon and ribavirin).
|
From initiation of treatment to 6 months after treatment discontinuation
|
Number of Participants Grouped by HIV-1 RNA Concentrations
Time Frame: At time of treatment discontinuation (whatever its date) and 6 months thereafter
|
Number of participants grouped by HIV-1 RNA concentrations (Detected vs.
Not Detected).
|
At time of treatment discontinuation (whatever its date) and 6 months thereafter
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Completed the First 24 and 48 Weeks of Treatment
Time Frame: From initiation of treatment to the first 48 weeks of treatment
|
Number of participants completed the first 24 and 48 weeks of treatment.
|
From initiation of treatment to the first 48 weeks of treatment
|
Number of Adverse Events by Severity Grade
Time Frame: From initiation of treatment to 6 months after treatment discontinuation
|
Number of adverse events (AE) by severity grade.
The severity grading scale is based on the DAIDS grading table, the grading scale ranging from grades 1 to 5: Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, and Grade 5 indicates death.
|
From initiation of treatment to 6 months after treatment discontinuation
|
Number of Participants Able to Perform Self-injections of Peg-interferon
Time Frame: From initiation of treatment to the first 48 weeks of treatment
|
Number of participants able to perform self-injections of peg-interferon.
|
From initiation of treatment to the first 48 weeks of treatment
|
Number of Participants With Ribavirin Compliance at ≥ 95%, 80% - 95%, and < 80%
Time Frame: From initiation of treatment to the first 48 weeks of treatment
|
Number of participants with ribavirin compliance at ≥ 95%, 80% - 95%, and < 80%.
|
From initiation of treatment to the first 48 weeks of treatment
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Infections
- Hepatitis C
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Antineoplastic Agents
- Interferons
- Ribavirin
Other Study ID Numbers
- PHPT-HCV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Peg-interferon + ribavirin under HIV physician supervision
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedInfections | Hepatitis C | HIVUnited States
-
Brooke Army Medical CenterT.R.U.E. Research FoundationCompleted
-
University of Turin, ItalyUnknown
-
Vertex Pharmaceuticals IncorporatedCompletedHepatitis | Hepatitis CUnited States
-
Centre hospitalier de l'Université de Montréal...Hoffmann-La Roche; Centre de Recherche du Centre Hospitalier de l'Université...Completed
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLCCompletedHCV Infection | Liver Cirrhosis, ExperimentalFrance
-
Biolex Therapeutics, Inc.CompletedHepatitis C, ChronicUnited States, Bulgaria, Puerto Rico, Romania
-
University of Modena and Reggio EmiliaMerck Sharp & Dohme LLCUnknownMenopause | Chronic Hepatitis CItaly
-
Tibotec BVBACompletedChronic Hepatitis CFrance, Spain, Belgium, Germany, Austria, Netherlands